Novo Nordisk appoints new VP North America

PRINCETON, N.J. A drug maker that specializes in diabetes care has appointed a new vice president.

Denmark-based Novo Nordisk announced Wednesday the appointment of Per Falk as VP clinical, medical and regulatory affairs for North America. Falk will report directly to Jerzy Gruhn, president of the company’s U.S. affiliate and SVP of its North America subsidiary.

Falk began working for the company in 2002 as VP, establishing its experimental medicine unit in Denmark, later working in Tokyo, where he was responsible for drug development and market authorization for the company in the Japan and Australia markets. He transferred to the United States last year.

“As a company, Novo Nordisk has exciting opportunities and ambitious targets in diabetes and biopharmaceuticals with the end goal of improving patients’ lives,” Gruhn said in a statement. “Dr. Falk is a proven asset to the company and is the ideal leader to help drive the development and marketing of new and lifesaving products to benefit millions of patients across the continent.”